Rofecoxib in the Acute Treatment of Migraine: A Randomized Controlled Clinical Trial
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Objective.—To investigate the efficacy, tolerability, and safety of rofecoxib and ibuprofen for acute migraine treatment. Background.—Rofecoxib was effective and well tolerated in a previous study of treatment of a single migraine attack. We sought to replicate these findings for a single attack and also study the clinical profile of rofecoxib in the acute treatment of multiple migraine attacks. Ibuprofen was included as a reference nonselective NSAID. Methods.—Adult migraineurs (n = 783) treated one migraine attack with either rofecoxib (25 or 50 mg), ibuprofen 400 mg, or placebo in a randomized, double‐blind study. Patients could elect to enroll in a 3‐month double‐blind extension phase. Results.—In the single‐attack phase, headache relief at 2 hours postdose was reported by 59.4%, 62.2%, and 57.7% of patients who took rofecoxib 25 mg, rofecoxib 50 mg, and ibuprofen 400 mg, respectively, versus 30.5% for placebo (all P < .001 vs placebo). The active drugs were statistically superior to placebo on a variety of additional measures. In the extension phase, the mean percentage of patients' attacks with headache relief at 2 hours postdose was 61.8% for rofecoxib 25 mg, 65.4% for rofecoxib 50 mg, and 59.3% for ibuprofen 400 mg. The mean percentage of patients' attacks with 24‐hour sustained headache relief was greater for rofecoxib 50 mg (52.0%) than for rofecoxib 25 mg (47.8%, P < .050) or ibuprofen (39.0%, P < .010). In the single‐attack phase, the adverse event rate was higher for rofecoxib 50 mg (37.8%) than placebo (27.8%, P < .050); rates were similar to placebo for rofecoxib 25 mg (32.0%, n.s.) and ibuprofen 400 mg (28.1%, n.s.). In the extension phase, treatment groups had similar adverse event rates. Conclusions.—Rofecoxib 25 and 50 mg and ibuprofen 400 mg were effective and generally well tolerated in the acute treatment of migraine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519
Self-citation
Cited by
EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force
Evers, S., Áfra, J., Frese, A., Goadsby, P. J., Linde, M., May, A., & Sándor, P. S. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02748.x · Cited by 892
A systematic review of adverse events in placebo groups of anti-migraine clinical trials
Amanzio, M., Corazzini, L. L., Vase, L., & Benedetti, F. (2009) · Pain · doi:10.1016/j.pain.2009.07.010 · Cited by 232
Haag, G., Diener, H.-C., May, A., Meyer, C., Morck, H., Straube, A., Wessely, P., & Evers, S. (2011) · The Journal of Headache and Pain · doi:10.1007/s10194-010-0266-4 · Cited by 78
Metadata
- Authors
- Saper, J., Dahlof, C., So, Y., Tfelt‐Hansen, P., Malbecq, W., Loeys, T., Barraclough, E., Klipfel, M., Lines, C., Visser, H., Reines, S., Yuen, E., & on behalf of the Rofecoxib Protocol 162 Study Group
- Venue
- Headache: The Journal of Head and Face Pain
- Publisher
- Wiley
- Published
- 2006-02
- Volume
- 46
- Issue
- 2
- Pages
- 264-275
- ISSN
- 0017-8748 (ISSN-L)
- 1526-4610
- OpenAlex
- W2017218082
- Cited by
- 38
- References
- 1
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rofecoxib in the Acute Treatment of Migraine: A Randomized Controlled Clinical Trial. https://app.cochat.ai/papers/10.1111/j.1526-4610.2006.00334.x
- The paper
- Saper, J., Dahlof, C., So, Y., Tfelt‐Hansen, P., Malbecq, W., Loeys, T., Barraclough, E., Klipfel, M., Lines, C., Visser, H., Reines, S., Yuen, E., & on behalf of the Rofecoxib Protocol 162 Study Group. (2006). Rofecoxib in the Acute Treatment of Migraine: A Randomized Controlled Clinical Trial. Headache: The Journal of Head and Face Pain. https://doi.org/10.1111/j.1526-4610.2006.00334.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.